Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 14/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20166540 | 1.00 | RIPK1 (0.51) | RIPK1HTR1AJAK2NTRK1SLC6A9 | |
| SCHEMBL22638897 | 0.88 | NR1H2 (0.39) | RIPK1HTR1AJAK2NTRK1SLC6A9 | |
| SCHEMBL22644516 | 0.88 | NR1H2 (0.39) | RIPK1HTR1AJAK2NTRK1SLC6A9 | |
| SCHEMBL22638850 | 0.88 | NR1H2 (0.39) | RIPK1HTR1AJAK2NTRK1SLC6A9 | |
| SCHEMBL22638974 | 0.88 | NR1H2 (0.39) | RIPK1HTR1AJAK2NTRK1SLC6A9 | |
| SCHEMBL22638852 | 0.88 | NR1H2 (0.39) | RIPK1HTR1AJAK2NTRK1SLC6A9 | |
| SCHEMBL22638804 | 0.88 | NR1H2 (0.39) | RIPK1HTR1AJAK2NTRK1SLC6A9 | |
| SCHEMBL22638805 | 0.88 | NR1H2 (0.39) | RIPK1HTR1AJAK2NTRK1SLC6A9 | |
| SCHEMBL22638952 | 0.88 | NR1H2 (0.39) | RIPK1HTR1AJAK2NTRK1SLC6A9 | |
| SCHEMBL30968257 | 0.88 | NR1H2 (0.39) | RIPK1HTR1AJAK2NTRK1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062735-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-02-27 | — | — | US | disclosed |
| US-20190345138-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | US | disclosed |
| US-20190345138-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | US | disclosed |
| EP-3541813-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018092089-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018092089-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345138-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | RIPK1 440/4885HTR1A 2170/4885JAK2 113/4885 |
| US-20200062735-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | RIPK1, RIPK4, RIPK3 | RIPK1 1/4885HTR1A 4158/4885JAK2 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.